Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL
Jennifer R. Brown(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Rayan Fardoun(Cancer Institute (WIA)), Samantha J. Shupe(Dana-Farber Cancer Institute), Kiyomi Mashima(Jichi Medical University), Aishath Naeem(Harvard University), Stacey M. Fernandes(Dana-Farber Cancer Institute)
Cited by 13
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752